Acorda Therapeutics has announced the US launch of the Inbrija levodopa dry powder inhaler in the US. In December 2018, he FDA approved Inbrija for the treatment of OFF episodes in Parkinson’s disease patients taking carbidopa/levodopa. The DPI will be available to patients by prescription through certain specialty pharmacies.
Acorda President and CEO Ron Cohen said, “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that Inbrija is now available to address this important unmet medical need, and that prescriptions are already being filled. Our field sales and medical teams have been meeting with movement disorder specialists to educate them about Inbrija and our Prescription Support Services center is available to help patients and physicians’ offices navigate access and reimbursement.”
Read the Acorda Therapeutics press release.
